PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022
December 21, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022 include initiating Phase 3 clinical study for...
PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch
December 20, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO and ANDERNACH, Germany, Dec. 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
December 14, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
Delivering LSD via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectivenessPursuing Phase 2 clinical studies in 2022 with LSD and...
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
November 30, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
November 24, 2021 07:30 ET
|
PharmaTher Holdings Ltd.
Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening...
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
November 11, 2021 07:59 ET
|
PharmaTher Holdings Ltd.
Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.Completing microneedle patch research programs...
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
November 03, 2021 07:30 ET
|
PharmaTher Holdings Ltd.
Focusing on partnership model for MicroDose-MN™ and MacroDose-MN™ patches to deliver psychedelics.Creating value and intellectual property protection for psychedelic programs.Providing pathways for...
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
November 01, 2021 09:30 ET
|
PharmaTher Holdings Ltd.
Completing IND-enabling studies with novel microneedle patch for ketamine, psilocybin, MDMA, LSD, and DMT.Expanding research in evaluating ibogaine and mescaline.Aiming for FDA Phase 1 and 2 clinical...
PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022
October 27, 2021 17:34 ET
|
PharmaTher Holdings Ltd.
TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its...
World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor
October 27, 2021 08:49 ET
|
PharmaTher Holdings Ltd.
Focus on expanding the delivery of controlled-substances in a microneedle patch.Evaluating potential uses of a microneedle patch for infectious diseases.Strengthening capabilities in the manufacturing...